A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

260 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-11

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A new drug, erdafitinib, became available for some patients with bladder cancer that has spread to other organs. To qualify, patients must have specific genetic changes in their tumors. Currently, doctors use tumor tissue samples to check for these genetic changes, but these samples might not accurately reflect the current state of the patient's cancer.

In this study, Investigators will test the patient's blood for these genetic changes in addition to the tumor tissue samples. It is thought that the blood test will give a more accurate result.

Investigators hope this study will help to find out if more patients can benefit from erdafitinib than the ones identified by tissue testing only.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Integrated Molecular Profiling in Advanced Cancers Trial

NCT01505400

Breast Cancer Non-small Cell Lung Cancer Colorectal Cancer +7 more

ACTIVE_NOT_RECRUITING

Development and Validation of Harbinger Health Test for Early Cancer Detection

NCT05435066

Cancer

COMPLETED

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

NCT03955913

Urothelial Cancer Receptors, Fibroblast Growth Factor

COMPLETED

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

NCT05366881

Brain Cancer Breast Cancer Bladder Cancer +17 more

RECRUITING

HRD Status Reference Standard Based on WGS

NCT06490380

Ovarian Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recently, the first targeted therapy for patients with metastatic urothelial cancer (mUC) received approval, i.e. erdafitinib. Erdafitinib is a pan-FGFR small molecule inhibitor. Approximately twenty percent of mUC patients' tumors harbor qualifying alterations in FGFR2 or FGFR3. Currently, standard testing uses archival tumor tissue. However, this type of testing may not be representative of a patient's clinically dominant tumor clone at the time of treatment initiation due to temporal and spatial biopsy bias of archival tissue testing.

In this study, patients will undergo circulating tumor DNA testing, in addition to conventional tissue testing, for treatment eligibility. Investigators hypothesize that blood-based ctDNA testing will provide a more accurate assessment of somatic FGFR status than same patient archival primary tissue.

This study's objectives are:

Objective 1 (Primary): To evaluate the diagnostic value of ctDNA testing against the "gold standard" of tissue testing.

Objective 2 (Secondary): To evaluate whether ctDNA may be a superior predictive marker by identifying actionable FGFR alterations that are currently missed on tissue assays.

Procedures:

* Medical history will be reviewed, including all previous anti-cancer treatments.
* A blood sample will be collected for ctDNA testing at the time of screening for FGFR alterations and at progression under erdafitinib therapy. Test results will be compared to archival tissue testing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Bladder Cancer Metastatic Urothelial Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metastatic Bladder Cancer

Patients with metastatic bladder cancer who will have archival tissue sent for FGFR testing.

FGFR Testing

Intervention Type GENETIC

Determine whether ctDNA testing for FGFR provides the same results as the standard tissue testing.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FGFR Testing

Determine whether ctDNA testing for FGFR provides the same results as the standard tissue testing.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with metastatic bladder cancer who are about to undergo tissue testing for FGFR mutations and who have blood samples drawn during the management of their disease are eligible to be included in this analysis.